LGVN Longeveron

Longeveron to Present at Oppenheimer 32nd Annual Healthcare Conference

Longeveron to Present at Oppenheimer 32nd Annual Healthcare Conference

MIAMI, March 15, 2022 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic, aging-related and life-threatening conditions, announced today that Geoff Green, Chief Executive Officer at Longeveron, will present at the upcoming Oppenheimer 32nd Annual Healthcare Conference on Wednesday, March 16, 2022. Details of Longeveron’s participation follow below:

  • Format: Virtual Company Presentation

    Date: Wednesday, March 16, 2022

    Time: 2:00 - 2:30 p.m. ET

The presentation can be accessed at or by visiting the investor relations section of the Company’s website (). Following the presentation, an archived replay will be available on Longeveron’s website.

About Longeveron Inc.

Longeveron is a clinical stage biotechnology company developing cellular therapies for specific aging-related and life-threatening conditions. The Company’s lead investigational product is the LOMECEL-B™ cell-based therapy product (“Lomecel-B”), which is derived from culture-expanded medicinal signaling cells (MSCs) that are sourced from bone marrow of young, healthy adult donors. Longeveron believes that by using the same cells that promote tissue repair, organ maintenance, and immune system function, it can develop safe and effective therapies for some of the most difficult disorders associated with the aging process and other medical disorders. Longeveron is currently sponsoring Phase 1 and 2 clinical trials in the following indications: Aging Frailty, Alzheimer’s disease, the Metabolic Syndrome, Acute Respiratory Distress Syndrome (ARDS), and hypoplastic left heart syndrome (HLHS). The Company’s mission is to advance Lomecel-B and other cell-based product candidates into pivotal Phase 3 trials, with the goal of achieving regulatory approvals, subsequent commercialization, and broad use by the healthcare community. Additional information about the Company is available at

Contact:

Brendan Payne

Stern Investor Relations

Tel: (212) 362-1200

Email:

Source: Longeveron



EN
15/03/2022

Underlying

LGVNLongeveron

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Longeveron

 PRESS RELEASE
Free
LGVN LONGEVERON

Longeveron Announces Closing of Private Placement of up to $30 Million

Longeveron Announces Closing of Private Placement of up to $30 Million $15 million upfront with a milestone-driven potential additional $15 million related to the Company’s anticipated pivotal clinical trial in Hypoplastic Left Heart Syndrome (HLHS) priced at the market under Nasdaq rules Private placement led by Coastlands Capital with participation from Janus Henderson Investors and other healthcare focused fundsInitial proceeds extend cash runway into 4Q26, past the anticipated pivotal Phase 2b ELPIS II clinical trial 3Q26 topline data readout MIAMI, March 11, 2026 (GLOBE NEWSWIRE) --...

6h / 30m 1 EN
 PRESS RELEASE
Free
LGVN LONGEVERON

Longeveron Announces Private Placement of up to $30 Million

Longeveron Announces Private Placement of up to $30 Million $15 million upfront with a milestone-driven potential additional $15 million related to the Company’s anticipated pivotal clinical trial in Hypoplastic Left Heart Syndrome (HLHS) priced at the market under Nasdaq rules Private placement led by Coastlands Capital with participation from Janus Henderson Investors and other healthcare focused fundsInitial proceeds extend cash runway into 4Q26, past the anticipated pivotal Phase 2b ELPIS II clinical trial 3Q26 topline data readout MIAMI, March 10, 2026 (GLOBE NEWSWIRE) -- Longeveron...

March 10, 2026 1 EN
 PRESS RELEASE
Free
LGVN LONGEVERON

Longeveron® Results of Phase 2b Clinical Trial Demonstrating Stem Cell...

Longeveron® Results of Phase 2b Clinical Trial Demonstrating Stem Cell Therapy Improved Condition of Patients with Age-Related Frailty Published in Cell Stem Cell MIAMI, Feb. 25, 2026 (GLOBE NEWSWIRE) -- (NASDAQ: LGVN), a clinical stage biotechnology company developing regenerative cell therapy for life-threatening rare pediatric and chronic aging-related conditions, today announced that results of its Phase 2b clinical trial were published today in , a Cell Press Journal. The Phase 2b results demonstrated that intravenous laromestrocel, a mesenchymal stem cell product, improved the phys...

February 25, 2026 1 EN
 PRESS RELEASE
Free
LGVN LONGEVERON

Longeveron® Appoints Stephen H. Willard as Chief Executive Officer

Longeveron® Appoints Stephen H. Willard as Chief Executive Officer Mr. Willard has a 30+ year track record of leadership across public and private sectors as CEO of multiple biotechnology and pharmaceutical firms, with an impressive history of delivering significant fundraises and strategic collaborationsCorporate focus on delivering top-line results from the pivotal Phase 2b clinical trial in Hypoplastic Left Heart Syndrome (HLHS), anticipated in the third quarter of 2026 Than Powell stepped down as interim CEO; will remain with the Company to support the leadership transition and continue...

February 13, 2026 1 EN
 PRESS RELEASE
Free
LGVN LONGEVERON

Longeveron Applauds Passage of the Mikaela Naylon Give Kids a Chance A...

Longeveron Applauds Passage of the Mikaela Naylon Give Kids a Chance Act and Reauthorization of Rare Pediatric Disease Priority Review Voucher Program The Mikaela Naylon Give Kids a Chance Act reauthorizes the Pediatric Priority Review Voucher (PPRV) Program and extends eligibility for medicines achieving U.S. FDA approval before September 2029The Pediatric Priority Review Voucher program encourages the development of treatments for rare pediatric diseasesU.S. FDA has awarded Longeveron’s laromestrocel Hypoplastic Left Heart Syndrome (HLHS) program Rare Pediatric Disease designation, Orphan...

February 5, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch